Richmond Pharmacology Opens New London Bridge Site
Posted:
3
March 2017
This decision marks the next step in Richmond Pharmacology’s continued growth, having already conducted over 300 studies in London since 2001, often in rare disease areas such as amyloidosis.
Richmond Pharmacology Opens New London Bridge Site
Dr Jorg Taubel, CEO of Richmond Pharmacology commented saying:“The opening of our new research facility is a sign of our continued commitment to working alongside the leading research hospitals and universities in the UK to deliver cutting-edge clinical research across vital disease areas.“Richmond are committed to making a significant and meaningful contribution to the health of the UK’s population and ensuring a sustainable future for the NHS through supporting the development of life changing and innovative medicines”
Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme
February 17, 2025
We are committed to embedding Environmental, Social, and Governance (ESG) principles into our clinical research operations to drive responsible and sustainable business growth...
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme
February 17, 2025
We are committed to embedding Environmental, Social, and Governance (ESG) principles into our clinical research operations to drive responsible and sustainable business growth...
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.